Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 3Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 7Bevacizumab 4sargramostim 2rindopepimut 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Cyclophosphamide 21-methyltryptophan 2ridaforolimus 1prinomastat 1pembrolizumab 1pamiparib 1marizomib 1interferon gamma-1b 1enzastaurin 1depatuxizumab mafodotin 1capmatinib 1Sucrose 1Spermine Synthase 1Radiosurgery 1Procarbazine 1ONC206 1NVP-BKM120 1Leflunomide 1Interferon-gamma 1Interferon-beta 1Immunotherapy 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gliosarcoma × Spermine Synthase × Clear all
NCT02052648 2024-03-27

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Lumos Pharma

Phase 1/2 Completed
160 enrolled 21 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡